LIVIVO - Search results -

Search results

Result 1 - 10 of total 17

Search options

Article ; Online: What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?

Garcia-Alvarez, Alejandro / Cubero, Jorge Hernando / Capdevila, Jaume

2022 Volume 24, Issue 4, Page(s) 451–461

Abstract: Purpose of review: Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of ... ...

Abstract	Purpose of review: Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of potential predictive biomarkers of response and efficacy of immunotherapy in neuroendocrine neoplasms (NENs) of gastro-entero-pancreatic origin. Recent findings: PD-L1 staining by immunohistochemistry has shown heterogeneous results across different studies in both well-differentiated neuroendocrine tumors (NETs) and poorly-differentiated neuroendocrine carcinomas (NECs). Tumor mutational burden in NENs is low, but seems to be higher in NECs. Immune infiltrate (CD3+ lymphocytes) at the tumor microenvironment (TME) is present in NETs and NECs. However, results from clinical trials with immunotherapy as monotherapy o combinations have shown limited efficacy. Further investigation into new strategies aside from anti-CTLA-4/PD-1/PD-L1 antibodies, validation of predictive biomarkers, and better population selection for clinical trials in NENs are more than needed in the near future.
MeSH term(s)	B7-H1 Antigen ; Carcinoma, Neuroendocrine ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy ; Neuroendocrine Tumors/pathology ; Pancreatic Neoplasms/drug therapy ; Stomach Neoplasms ; Tumor Microenvironment
Chemical Substances	B7-H1 Antigen ; Immunologic Factors
Language	English
Publishing date	2022-02-16
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-022-01235-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: What is the status of immunotherapy in thyroid neoplasms?

Garcia-Alvarez, Alejandro / Hernando, Jorge / Carmona-Alonso, Ana / Capdevila, Jaume

Frontiers in endocrinology

2022 Volume 13, Page(s) 929091

Abstract: Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of potential predictive ... ...

Abstract	Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of potential predictive biomarkers of response and efficacy of immunotherapy in thyroid neoplasms. Programmed death-ligand 1 (PD-L1) staining by immunohistochemistry has shown higher expression in anaplastic thyroid cancer (ATC) compared to other subtypes. The tumor mutational burden in thyroid neoplasms is low but seems to be higher in ATC. Immune infiltrates in the tumor microenvironment (TME) differ between the different thyroid neoplasm subtypes. In general, differentiated thyroid cancer (DTC) has a higher number of tumor-associated lymphocytes and regulatory T cells (Tregs), while ATC and medullary thyroid cancer (MTC) display a high density of tumor-associated macrophages (TAMs). Nevertheless, results from clinical trials with immunotherapy as monotherapy or combinations have shown limited efficacy. Further investigation into new strategies aside from anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)/programmed death 1 (PD-1)/PD-L1 antibodies, validation of predictive biomarkers, and better population selection for clinical trials in thyroid neoplasms is more than needed in the near future.
MeSH term(s)	B7-H1 Antigen ; Humans ; Immunotherapy ; Thyroid Carcinoma, Anaplastic/drug therapy ; Thyroid Neoplasms/drug therapy ; Tumor Microenvironment
Chemical Substances	B7-H1 Antigen
Language	English
Publishing date	2022-08-05
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2592084-4
ISSN	1664-2392
ISSN	1664-2392
DOI	10.3389/fendo.2022.929091
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies.

Garcia-Alvarez, Alejandro / Papakonstantinou, Andri / Oliveira, Mafalda

Cancers

2021 Volume 13, Issue 12

Abstract: Development of brain metastases can occur in up to 30-50% of patients with breast cancer, representing a significant impact on an individual patient in terms of survival and quality of life. Patients with HER2-positive breast cancer have an increased ... ...

Abstract	Development of brain metastases can occur in up to 30-50% of patients with breast cancer, representing a significant impact on an individual patient in terms of survival and quality of life. Patients with HER2-positive breast cancer have an increased risk of developing brain metastases; however, screening for brain metastases is not currently recommended due to the lack of robust evidence to support survival benefit. In recent years, several novel anti-HER2 agents have led to significant improvements in the outcomes of HER2-positive metastatic breast cancer. Despite these advances, brain and leptomeningeal metastases from HER2-positive breast cancer remain a significant cause of morbidity and mortality, and their optimal management remains an unmet need. This review presents an update on the current and novel treatment strategies for patients with brain metastases from HER2-positive breast cancer and discusses the open questions in the field.
Language	English
Publishing date	2021-06-11
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13122927
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Current Perspectives and Novel Strategies of

Garcia-Alvarez, Alejandro / Ortiz, Carolina / Muñoz-Couselo, Eva

OncoTargets and therapy

2021 Volume 14, Page(s) 3709–3719

Abstract: Melanoma is the deadliest cutaneous cancer. Activating mutations ... ...

Abstract	Melanoma is the deadliest cutaneous cancer. Activating mutations in
Language	English
Publishing date	2021-06-09
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2495130-4
ISSN	1178-6930
ISSN	1178-6930
DOI	10.2147/OTT.S278095
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Drug Development in Neuroendocrine Tumors: What Is on the Horizon?

Garcia-Alvarez, Alejandro / Hernando Cubero, Jorge / Capdevila, Jaume

Current treatment options in oncology

2021 Volume 22, Issue 5, Page(s) 43

Abstract: Opinion statement: Neuroendocrine neoplasms (NENs) constitute a heterogenous group of malignancies. Translational research into NEN cell biology is the cornerstone for drug development strategies in this field. Somatostatin receptor type 2 (SSTR2) ... ...

Abstract	Opinion statement: Neuroendocrine neoplasms (NENs) constitute a heterogenous group of malignancies. Translational research into NEN cell biology is the cornerstone for drug development strategies in this field. Somatostatin receptor type 2 (SSTR2) expression is the hallmark of well-differentiated neuroendocrine tumors (NETs). Somatostatin analogs and peptide receptor radionuclide therapy (PRRT) form the basis of anti-SSTR2 treatment onto new combination strategies, antibody-drug conjugates and bispecific antibodies. Classical pathways involved in NET development (PI3K-Akt-mTOR and antiangiogenics) are reviewed but new potential targets for NET treatment will be explored. Epigenetic drugs have shown clinical activity in monotherapy and preclinical combination strategies are more than attractive. Immunotherapy has shown opposite results in different NEN settings. Although the NOTCH pathway has been targeted with disappointing results, new strategies are being developed. Finally, after years of solid preclinical evidence on different genetically engineered oncolytic viruses, clinical trials for refractory NET patients are now ongoing.
MeSH term(s)	Angiogenesis Inhibitors/therapeutic use ; Drug Development/trends ; Epigenesis, Genetic/drug effects ; Humans ; Immunoconjugates/therapeutic use ; Immunotherapy ; Neuroendocrine Tumors/drug therapy ; Neuroendocrine Tumors/genetics ; Neuroendocrine Tumors/metabolism ; Oncolytic Viruses ; Protein Kinase Inhibitors/therapeutic use ; Radioisotopes/chemistry ; Radioisotopes/therapeutic use ; Receptors, Peptide/chemistry ; Receptors, Peptide/therapeutic use ; Receptors, Somatostatin/antagonists & inhibitors ; Receptors, Somatostatin/genetics ; Receptors, Somatostatin/metabolism ; Signal Transduction/drug effects ; Somatostatin/analogs & derivatives ; Somatostatin/therapeutic use
Chemical Substances	Angiogenesis Inhibitors ; Immunoconjugates ; Protein Kinase Inhibitors ; Radioisotopes ; Receptors, Peptide ; Receptors, Somatostatin ; SSTR2 protein, human ; Somatostatin (51110-01-1)
Language	English
Publishing date	2021-03-30
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057351-0
ISSN	1534-6277 ; 1527-2729
ISSN (online)	1534-6277
ISSN	1527-2729
DOI	10.1007/s11864-021-00834-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5523: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48].

Hernando, Jorge / Roca-Herrera, Maria / García-Álvarez, Alejandro / Raymond, Eric / Ruszniewski, Philippe / Kulke, Matthew H / Grande, Enrique / Carbonero, Rocío García / Castellano, Daniel / Salazar, Ramón / Ibrahim, Toni / Teule, Alex / Alonso, Vicente / Fazio, Nicola / Valle, Juan W / Tafuto, Salvatore / Carmona, Ana / Navarro, Victor / Capdevila, Jaume

European journal of cancer (Oxford, England : 1990)

2024 Volume 203, Page(s) 114061

Language	English
Publishing date	2024-04-12
Publishing country	England
Document type	Published Erratum
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2024.114061
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

Article: Impact of the COVID-19 pandemic in the early-onset colorectal cancer.

Translational oncology

2023 Volume 32, Page(s) 101668

Abstract: The COVID19 pandemic has affected the spectrum of cancer care worldwide. Early onset colorectal cancer (EOCRC) is defined as diagnosis below the age of 50. Patients with EOCRC faced multiple challenges during the COVID19 pandemic and in some institutions ...

Abstract	The COVID19 pandemic has affected the spectrum of cancer care worldwide. Early onset colorectal cancer (EOCRC) is defined as diagnosis below the age of 50. Patients with EOCRC faced multiple challenges during the COVID19 pandemic and in some institutions it jeopardized cancer diagnosis and care delivery. Our study aims to identify the clinicopathological features and outcomes of patients with EOCRC in our Centre during the first wave of the pandemic in comparison with the same period in 2019 and 2021. Patients with EOCRC visited for the first time at Vall d'Hebron University Hospital in Spain from the 1st March to 31st August of 2019, 2020 and 2021 were included in the analysis. 177 patients with EOCRC were visited for the first time between 2019 and 2021, of which 90 patients met the inclusion criteria (2019: 30 patients, 2020: 29 patients, 2021: 31 patients). Neither differences in frequency nor in stage at diagnosis or at first visit during the given periods were observed. Of note, indication of systemic therapy in the adjuvant or metastatic setting was not altered. Days to treatment initiation and enrollment in clinical trials in this subpopulation was not affected due to the COVID-19 outbreak.
Language	English
Publishing date	2023-04-05
Publishing country	United States
Document type	Journal Article
ZDB-ID	2443840-6
ISSN	1936-5233
ISSN	1936-5233
DOI	10.1016/j.tranon.2023.101668
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.

Mirallas, Oriol / Filippi-Arriaga, Francesca / Hernandez Hernandez, Irene / Aubanell, Anton / Chaachou, Anas / Garcia-Alvarez, Alejandro / Hernando, Jorge / Martínez-Saez, Elena / Biagetti, Betina / Capdevila, Jaume

Frontiers in endocrinology

2021 Volume 12, Page(s) 731631

Abstract: Nelson's syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing's disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial ... ...

Abstract	Nelson's syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing's disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson's syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
MeSH term(s)	Adenoma/complications ; Adenoma/drug therapy ; Adenoma/pathology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Capecitabine/administration & dosage ; Humans ; Male ; Middle Aged ; Nelson Syndrome/complications ; Nelson Syndrome/drug therapy ; Neoplasm Invasiveness ; Pituitary Neoplasms/complications ; Pituitary Neoplasms/drug therapy ; Pituitary Neoplasms/pathology ; Spain ; Temozolomide/administration & dosage ; Treatment Outcome ; Tumor Burden
Chemical Substances	Capecitabine (6804DJ8Z9U) ; Temozolomide (YF1K15M17Y)
Language	English
Publishing date	2021-11-11
Publishing country	Switzerland
Document type	Case Reports ; Journal Article
ZDB-ID	2592084-4
ISSN	1664-2392
ISSN	1664-2392
DOI	10.3389/fendo.2021.731631
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.

Cuesta-Borràs, Estefania / Salvans, Cándida / Arqués, Oriol / Chicote, Irene / Ramírez, Lorena / Cabellos, Laia / Martínez-Quintanilla, Jordi / Mur-Espinosa, Alex / García-Álvarez, Alejandro / Hernando, Jorge / Tejedor, Juan Ramón / Mirallas, Oriol / Élez, Elena / Fraga, Mario F / Tabernero, Josep / Nuciforo, Paolo / Capdevila, Jaume / Palmer, Héctor G / Puig, Isabel

Cell reports

2023 Volume 42, Issue 8, Page(s) 112927

Abstract: Tumor relapse is linked to rapid chemoresistance and represents a bottleneck for cancer therapy success. Engagement of a reduced proliferation state is a non-mutational mechanism exploited by cancer cells to bypass therapy-induced cell death. Through ... ...

Abstract	Tumor relapse is linked to rapid chemoresistance and represents a bottleneck for cancer therapy success. Engagement of a reduced proliferation state is a non-mutational mechanism exploited by cancer cells to bypass therapy-induced cell death. Through combining functional pulse-chase experiments in engineered cells and transcriptomic analyses, we identify DPPA3 as a master regulator of slow-cycling and chemoresistant phenotype in colorectal cancer (CRC). We find a vicious DPPA3-HIF1α feedback loop that downregulates FOXM1 expression via DNA methylation, thereby delaying cell-cycle progression. Moreover, downregulation of HIF1α partially restores a chemosensitive proliferative phenotype in DPPA3-overexpressing cancer cells. In cohorts of CRC patient samples, DPPA3 overexpression acts as a predictive biomarker of chemotherapeutic resistance that subsequently requires reduction in its expression to allow metastatic outgrowth. Our work demonstrates that slow-cycling cancer cells exploit a DPPA3/HIF1α axis to support tumor persistence under therapeutic stress and provides insights on the molecular regulation of disease progression.
Language	English
Publishing date	2023-08-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2649101-1
ISSN	2211-1247 ; 2211-1247
ISSN (online)	2211-1247
ISSN	2211-1247
DOI	10.1016/j.celrep.2023.112927
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours.

Hernando, Jorge / Roca-Herrera, Maria / García-Álvarez, Alejandro / Raymond, Eric / Ruszniewski, Philippe / Kulke, Matthew H / Grande, Enrique / García-Carbonero, Rocío / Castellano, Daniel / Salazar, Ramón / Ibrahim, Toni / Teule, Alex / Alonso, Vicente / Fazio, Nicola / Valle, Juan W / Tafuto, Salvatore / Carmona, Ana / Navarro, Victor / Capdevila, Jaume

European journal of cancer (Oxford, England : 1990)

2023 Volume 188, Page(s) 39–48

Abstract: Purpose: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in oncological systemic therapies is still unknown, and there is a lack of evidence specially in uncommon neoplasms like ... ...

Abstract	Purpose: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in oncological systemic therapies is still unknown, and there is a lack of evidence specially in uncommon neoplasms like neuroendocrine tumours (NET). In the present study, we combine the differential toxicities by sex in five published clinical trials with multikinase inhibitors (MKI) in gastroenteropancreatic (GEP) NET. Methods: We performed a pooled univariate analysis of reported toxicity in patients treated in five phase 2 and phase 3 clinical trials with MKI in the GEP NET setting: sunitinib (SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT). Differential toxicities between male and female patients were evaluated considering relationship with study drug and different weights of each trial by random effect adjustment. Results: We found nine toxicities which were more frequent in female patients (leukopenia, alopecia, vomiting, headache, bleeding, nausea, dysgeusia, neutrophil count decreased and dry mouth) and two toxicities being more frequent in male patients (Anal Symptoms and Insomnia). Asthenia and diarrhoea were the only severe (Grade 3-4) toxicities more frequent in female patients. Conclusions: Sex-related differences in toxicity with the MKI treatment require targeted information and individualised management of patients with NET. Differential reporting of toxicity should be promoted when clinical trials are published.
MeSH term(s)	Humans ; Female ; Male ; Neuroendocrine Tumors/drug therapy ; Sex Characteristics ; Sunitinib/therapeutic use ; Sorafenib/therapeutic use ; Bevacizumab/therapeutic use
Chemical Substances	Sunitinib (V99T50803M) ; Sorafenib (9ZOQ3TZI87) ; Bevacizumab (2S9ZZM9Q9V)
Language	English
Publishing date	2023-04-23
Publishing country	England
Document type	Journal Article
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2023.04.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito